All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Previous studies have emphasized the importance of vascular endothelial cells, which are particularly susceptible to and actively participate in the pathophysiology of tissue injury induced by ischemia-reperfusion (IR). In the clinic, the chronic dysfunction of these endothelial cells leads to atherosclerosis and also acts as an important independent predictor of negative prognosis for coronary artery diseases \[[@pone.0178838.ref001]\]. As it can act as a determinant factor reflecting a tissue's capacity to recover from IR, interventions to protect the endothelium from IR has become an area of great clinical interest. In a human forearm IR model, both exposure to brief periods of ischemia (ischemic preconditioning) \[[@pone.0178838.ref002]\] and some pharmacologic stimuli such as sildenafil, rosuvastatin and exenatide have been shown to reduce IR-induced endothelial dysfunction \[[@pone.0178838.ref003]--[@pone.0178838.ref005]\].

In pharmaceuticals, several molecules have been identified as mediators in maintaining endothelial function. Nitric oxide (NO) is considered one of the most significant as it is known to be involved in several of the protective mechanisms \[[@pone.0178838.ref006]\], including the up-regulation of the cyclooxygenase (COX)-2 enzyme \[[@pone.0178838.ref007]--[@pone.0178838.ref009]\]. Studies show that prostaglandins mediate the cardioprotective effects of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, against IR injury \[[@pone.0178838.ref007]\]. Rosuvastatin has also been demonstrated to induce such a preconditioning response mediated through a COX-2-dependent mechanism \[[@pone.0178838.ref004]\].

In complementary and alternative medicine, acupuncture is commonly used to alleviate pain but it has also been widely explored in the treatment of hypertension \[[@pone.0178838.ref010]\] and many cardiovascular diseases \[[@pone.0178838.ref011]--[@pone.0178838.ref014]\]. Acupuncture has been reported to reduce sympathetic tone and enhance the generation of endothelial NO \[[@pone.0178838.ref015]\]. Animal studies in hypertensive models have also shown that acupuncture, especially electroacupuncture (EA), works via stimulation of sensory nerve fibers that decrease sympathetic outflow and norepinephrine release, while increasing c-fos expression in the nucleus of the solitary tract \[[@pone.0178838.ref016]\]. Yet, the mechanisms at work in prevention of endothelial dysfunction are still under exploration.

A preliminary study in patients with hypertension suggested that acupuncture improved FMD \[[@pone.0178838.ref017]\], but it did not explore the mechanisms. Since then no other clinical study has investigated how acupuncture protects against IR-induced endothelial dysfunction in a human model. Therefore we designed two protocols to test (1) whether acupuncture can prevent impairment in IR-induced endothelial dysfunction and (2) whether this effect is mediated by a COX-2 dependent pathway in a human forearm model of IR-induced endothelial dysfunction.

Methods {#sec006}
=======

2.1 Patient population {#sec007}
----------------------

From May 1^st^ to August 23^rd^ 2014, healthy nonsmoking volunteers (25 to 40 years of age) were recruited and those currently taking medication for hypertension, diabetes or other chronic diseases, suffering from hepatic, renal, thyroid, or cerebrovascular diseases, currently pregnant, or has body mass index greater than 25 kg/m^2^ were excluded. After trial commencement, we further excluded those taking dietary supplements or enrolled in another clinical trial. Twenty one people were assessed for eligibility and twenty people fulfilled the inclusion criteria. All of them completed two sessions of treatment for protocol 1. Among the participants, seven volunteered to further take part in the celebrex experimental group (protocol 2) ([Fig 1](#pone.0178838.g001){ref-type="fig"}).

![Flow diagram.\
Consolidated standards of reporting trials flow diagram of the randomized controlled trial.](pone.0178838.g001){#pone.0178838.g001}

2.2 Study design {#sec008}
----------------

This study was a prospective, randomized, subject and assessor blind, crossover and placebo-controlled clinical trial conducted in the Division of Cardiology, Department of Internal Medicine, and the Department of Acupuncture and Moxibustion, Kyung Hee University Medical Centre, Seoul, Republic of Korea. Data were collected in the Division of Cardiology, Kyung Hee University Medical Centre. This study protocol was approved by the institutional review board (IRB) of Kyung Hee University Hospital (approval date: April 11^th^, 2014, No. 1403--01) and was developed in accordance with the Declaration of Helsinki. The study protocol was explained in detail to eligible participants, and written informed consent was obtained from all subjects. ₩ 100,000 (approximately \$ 90) was given to each participant per session as compensation for their time. The study was registered at Clinical Trials.gov: NCT02255006 (<https://clinicaltrials.gov/ct2/show/NCT02255006>). There was a delay in registering this study due to language and administrative issues. The authors confirm that all ongoing and related trials for this intervention are registered.

### 2.2.1. Protocol 1: Effect of electroacupuncture (EA) on IR-induced endothelial dysfunction {#sec009}

Protocol 1 was performed by a randomized, subject and assessor blind, crossover and placebo-controlled manner. Twenty healthy nonsmoking volunteers (9 males; ages 29.6 ± 2.6 years) were enrolled in the trial. All subjects were asked to abstain from caffeine and drugs, including supplemental vitamins, for the duration of the study. Initially, endothelium-dependent FMD of the brachial artery (BA) and nitroglycerin-mediated endothelial independent dilation (NMD) were measured before and after IR (15 minutes of ischemia at the level of the proximal upper arm followed by 15 minutes of reperfusion) ([Fig 2](#pone.0178838.g002){ref-type="fig"}). EA was performed beginning 10 minutes after ischemia to the end of reperfusion (20 minutes total). All subjects underwent a seven-day wash-out period. Seven days later, the subjects returned to participate in the crossover study (i.e., EA or sham EA), and the protocol described above was repeated. Supine blood pressure (BP) was taken and recorded before the exam and at the end of the exam described in protocol 1.

![Study protocol.\
Ischemia-reperfusion and flow-mediated dilatation were measured and subjects received electroacupuncture or sham electroacupuncture according to the assigned sequence of treatment phases. BA: basal artery, EA: electroacupuncture, FMD: flow-mediated dilatation, IR: ischemia-reperfusion, NMD: nitroglycerin-mediated endothelial independent dilation.](pone.0178838.g002){#pone.0178838.g002}

### 2.2.2 Randomization and blinding {#sec010}

Participants were randomly assigned to either EA or sham EA using a computerized random allocation sequence with a permutable block design. A member who had no contact with any of the participants notified only the acupuncturist of the participant allocation right before treatment by phone. Assessors were concealed to all of the allocations, and the participants were naturally blinded because the point of real EA and sham EA were very close, the study was conducted in a semi-lit evaluation room limiting view of the treatment area, and most were acupuncture naïve. The acupuncturists only came into the study room to insert the needles and to apply EA while refraining from any conversation.

### 2.2.3 Protocol 2: Effect of celecoxib pre-treatment {#sec011}

Protocol 2 was performed in a non-randomized, non-blinded manner. After completing protocol 1, seven volunteers were further recruited to participate in protocol 2. They underwent a fifteen-day wash-out period. Volunteers were administered the selective COX-2 inhibitor, celecoxib (Cerebrex, Pfizer) 200 mg twice a day for five days. The last dose of celecoxib was administered on the morning of FMD measurement. Subjects underwent FMD measurement before and after IR, as described above. EA was performed for 20 minutes as in the previously described method.

### 2.2.4 EA and sham EA {#sec012}

For active EA treatment, unilateral PC5, PC6, ST36, and ST37 were used ([S1 Fig](#pone.0178838.s001){ref-type="supplementary-material"}). PC5 and PC6 are located proximal to the base of the palmar wrist crease above the median nerve. ST36 and ST37 are located below the depression point lateral to the patellar ligament and lateral to the anterior tubercle of the tibia on the anterior aspect of the knee. PC5 and ST37 were added to connect the poles to PC6 and ST36. Previous clinical studies have consistently shown that acupuncture stimulation on PC6 plus ST36 improves endothelial function \[[@pone.0178838.ref017],[@pone.0178838.ref018]\].

Disposable, sterile needles (0.25 mm x 40 mm, Dongbang Acupuncture Inc., Boryung, Korea) and a low-frequency electrical stimulator (ES-160, ITO, Japan) were used. Each needle was inserted at a 90 degree angle to a depth of 1cm at PC5 and PC6 and to a depth of 2 cm at ST36 and ST37. Then, the practitioner rotated the needle several times and induced de-qi (acupuncture-evoked sensations such as heaviness, numbness, soreness, or distention). Thereafter, needles were connected to the pole and electrical stimulation was applied with a 2 Hz continuous wave current. Intensity was increased until participants felt stimulation but not discomfort, and their muscles twitched slightly. EA was performed after ten minutes of inducing ischemia to the end of reperfusion, 20 minutes in total. Acupuncture treatment was conducted by Doctors of Korean Medicine educated by the College of Korean Medicine for six years and licensed by the Korean Ministry of Health and Welfare; with more than four years of clinical experience. All practitioners were trained to follow the study protocol.

For sham EA treatment, four non-acupuncture points (located 10--20 mm lateral to PC5, PC6, ST36, ST37 and not above a meridian line) were inserted to a depth of 0.5 cm at a 90 degree angle. Manual manipulation was not conducted, and de-qi sensations were not induced. Needles were connected to the pole and identical sounds were generated as in the active EA group, but electrical stimulation was not delivered to the sham EA group. After each session, any bleeding, bruises, or unintended effects due to EA were identified and documented. These EA and sham EA methods have been used successfully in previous clinical trials \[[@pone.0178838.ref017], [@pone.0178838.ref018]\].

### 2.2.5 Measurement of FMD {#sec013}

Subjects were asked to rest for ten minutes in the supine position prior to each study protocol. The FMD and NMD measurements were performed by two independent operators. Brachial artery images were obtained using a commercially available system (Vivid 7, GE Vingmed, Horten, Norway) equipped with a 14-MHz linear array transducer. The ECG-gated, end-diastolic, longitudinal, B-mode images were digitally stored on the hard disk of the instrument for on-line and off-line analysis. For FMD measurement, the baseline BA diameter was averaged from six separate images taken at five-second intervals. Subsequently, a pneumatic cuff placed at the level of the lower arm was inflated to 200 mmHg for five minutes. After wrist-cuff deflation, the BA diameter was re-examined and averaged from six separate images taken at five-second intervals. FMD was calculated as the percent maximum increase in arterial diameter. After a ten-minute rest period to allow restoration of baseline conditions, NMD was again assessed by obtaining two-dimensional images before and three minutes after administration of 50 μg of GTN in order to characterize endothelial-independent vasodilation. The artery diameter was calculated from the trailing edge of the intima-blood interface to the leading edge semi-automatically using a modified version of Image J software (Version 1.47 t, National Institutes of Health, Bethesda, MD, USA) as well as custom-designed software. Baseline and post-IR (reactive hyperemia) blood flows were measured using pulsed-wave Doppler as an average velocity-time integral for the first five cardiac cycles after cuff deflation and were multiplied by heart rate and vessel cross-sectional area. The reproducibility of this method in our laboratory was previously reported several times \[[@pone.0178838.ref005],[@pone.0178838.ref019],[@pone.0178838.ref020]\]. A diagram illustrating the study method is shown in [S2 Fig](#pone.0178838.s002){ref-type="supplementary-material"}.

2.3 Statistical analysis {#sec014}
------------------------

Sample size was calculated as follows. In our preceding research among healthy subjects, FMD before IR injury was 12.0 ± 6.2, and after IR was 4.6 ± 3.6 \[[@pone.0178838.ref005]\]. Exenatide was proven to prevent IR injury 100% (FMD before IR = 15.0 ± 7.1, FMD after IR = 15.0 ± 5.9). Yet, the prevention effect of acupuncture has not been studied. We assumed that acupuncture could improve FMD after IR injury about 30%. Targeted number of subjects is total 34 (17 in each group), considering 5% type 1 error and 80% power. Considering drop-out rate of 15%, total 40 subjects are needed. As this study is a crossover trial, 20 subjects are needed. Data were presented as the mean ± standard deviation. Within-group comparisons were performed with paired *t*-test or Wilcoxon signed rank test. Between-group differences and the interaction of IR and group randomization were studied with a two-way analysis of variance. Post hoc comparisons were performed using the Bonferroni correction. A *p*-value less than 0.05 was considered statistically significant. Multivariate analysis (adjusted age and gender) was performed to determine whether acupuncture could protect endothelial dysfunction defined as FMD \< 6%. All analyses were performed with SPSS software (Windows version 17.0, Chicago, Illinois, USA) by a statistician blinded to participant allocation. The CONSORT checklist, original, and translated version of the trial protocol are available ([S1](#pone.0178838.s003){ref-type="supplementary-material"}, [S2](#pone.0178838.s004){ref-type="supplementary-material"} and [S3](#pone.0178838.s005){ref-type="supplementary-material"} Files).

Results {#sec015}
=======

3.1 Baseline characteristics {#sec016}
----------------------------

All of the eligible participants completed the trial without dropping out. The baseline demographic characteristics of the subjects in protocol 1 and protocol 2 are summarized in [Table 1](#pone.0178838.t001){ref-type="table"}. There were no reported adverse effects. The individual data points behind means, medians and variance measures presented in the results are available ([S4 File](#pone.0178838.s006){ref-type="supplementary-material"}).

10.1371/journal.pone.0178838.t001

###### Baseline demographic characteristics of subjects.

![](pone.0178838.t001){#pone.0178838.t001g}

  -----------------------------------------------------------------------------------------
  Variables                                      Protocol 1\           Protocol 2\
                                                 Subjects (*n* = 20)   Subjects (*n* = 7)
  ---------------------------------------------- --------------------- --------------------
  Age (yr)                                       29.6 ± 2.6            28.2 ± 2.3

  Male (*n*)                                     9 (45%)               5 (71%)

  Smoker (n)                                     0                     0

  Body mass index (kg/m^2^)                      20.5 ± 2.4            21.4 ± 1.9

  Hemoglobin (g/dL)                              14.7 ± 1.0            14.7 ± 1.5

  Platelet count (10^3^/μL)                      233.3 ± 50.5          248.5 ± 35.5

  Aspartate aminotransferase (U/L)               24.8 ± 4.2            21.1 ± 5.2

  Alanine aminotransferase (U/L)                 19.4 ± 9.3            19.0 ± 8.9

  Creatinine (mg/dL)                             0.7 ± 0.1             0.7 ± 0.1

  Fasting glucose (mg/dL)                        91.0 ± 5.8            96.4 ± 11.9

  Total cholesterol (mg/dL)                      192.6 ± 38.3          177.6 ± 24.3

  Triglyceride (my/dL)                           83.7 ± 51.1           64.2 ± 17.1

  High-density lipoprotein cholesterol (mg/dL)   114.4 ± 34.1          98.6 ± 18.5

  Low-density lipoprotein cholesterol (mg/dL)    64.0 ± 13.4           63.7 ± 10.8
  -----------------------------------------------------------------------------------------

3.2 Protocol 1 {#sec017}
--------------

EA intervention had no effect on arterial BP compared with sham EA (systolic BP: EA 113.05 ± 12.99 mmHg vs. sham EA: 113.75 ± 13.26 mmHg, P = NS, diastolic BP: EA 66.6 ± 7.71 mmHg vs. placebo EA 67.4 ± 9.45 mmHg, P = NS). EA and sham EA had no effect on baseline BA diameter before and after IR ([Table 2](#pone.0178838.t002){ref-type="table"}, p = NS).

10.1371/journal.pone.0178838.t002

###### Results of arterial diameter in protocols 1 and 2.

![](pone.0178838.t002){#pone.0178838.t002g}

                    Pre-IR         Post-IR                                                                                        
  ----------------- -------------- ------------- ------------- ---------------------------------------------------- ------------- -------------
  **Protocol 1**                                                                                                                  
   EA               10.96 ± 5.30   3.42 ± 0.55   3.77 ± 0.50   9.47 ± 5.23[^\#^](#t002fn003){ref-type="table-fn"}   3.51 ± 0.60   3.83 ± 0.66
   Sham             11.41 ± 3.10   3.41 ± 0.48   3.80 ± 0.54   4.49 ± 2.04[\*](#t002fn002){ref-type="table-fn"}     3.47 ± 0.48   3.63 ± 0.51
  **Protocol 2**                                                                                                                  
   Celecoxib + EA   11.05 ± 3.27   3.43 ± 0.32   3.81 ± 0.36   4.20 ± 1.68[\*](#t002fn002){ref-type="table-fn"}     3.66 ± 0.53   3.81 ± 0.53

Baseline data refer to brachial artery diameter before upper arm cuff occlusion. Values are the mean ± standard deviation. EA: electroacupuncture, FMD: flow-mediated dilatation; IR: ischemia-reperfusion.

\*p \< 0.05 vs. the corresponding value before IR.

^\#^p = 0.002 compared with sham EA.

### 3.2.1 Effects of IR injury after sham EA {#sec018}

In the sham EA group, BA diameter and blood flow values were not different from baseline values before and after IR (p = NS). However, post-IR FMD was significantly decreased compared with the pre-IR level (Pre-IR: 11.41 ± 3.10%; Post-IR: 4.49 ± 2.04%, p \< 0.001, [Table 2](#pone.0178838.t002){ref-type="table"} and [Fig 3](#pone.0178838.g003){ref-type="fig"}). However, there was no significant difference in blood flow (Pre-IR: 237.4 ± 158.5 mL/min; Post-IR: 188.6 ± 87.1 mL/min, p = NS, [Table 3](#pone.0178838.t003){ref-type="table"}) and NMD (pre-IR: 14.22 ± 3.76%; post- IR: 11.53 ± 4.36%, p = NS).

![Box plots of the flow-mediated dilatation responses before and after ischemia-reperfusion (protocol 1).\
Left: In the sham group, FMD was significantly blunted after IR. Right: Electroacupuncture completely prevented the impairment in endothelium-dependent vasodilation induced by IR. Boxes show interquartile ranges; the lower and upper boundaries of the boxes indicate the 25^th^ and 75^th^ percentile levels, respectively, and the horizontal lines within the boxes indicate the median levels. FMD: flow-mediated dilatation, IR: ischemia-reperfusion.](pone.0178838.g003){#pone.0178838.g003}

10.1371/journal.pone.0178838.t003

###### Results of brachial artery blood flow in protocols 1 and 2.

![](pone.0178838.t003){#pone.0178838.t003g}

  Blood Flow        Blood Flow Pre-IR   Blood Flow Post-IR                  
  ----------------- ------------------- -------------------- -------------- ---------------
  **Protocol 1**                                                            
   EA               74.47 ± 40.2        240.6 ± 148.8        68.9 ± 46.9    204.9 ± 111.1
   Sham             77.3 ± 45.9         237.4 ± 158.5        67.5 ± 28.9    188.6 ± 87.1
  **Protocol 2**                                                            
   Celecoxib + EA   85.6 ± 37.6         242.9 ± 57.6         70.34 ± 15.2   209.2 ± 49.6

Values are the mean ± standard deviation. IR indicates ischemia-reperfusion.

EA: electroacupuncture.

### 3.2.2 Effects of IR injury after EA {#sec019}

Similarly, BA diameter and blood flow values were not different from baseline values before and after IR (p = NS) in the EA group. In contrast, EA restored the FMD reduction that was observed in the sham EA group after IR injury (pre-IR: 10.96 ± 5.30%; Post-IR: 9.47 ± 5.23%, p = NS, p \< 0.05 compared with sham EA after IR; two-way ANOVA, [Table 2](#pone.0178838.t002){ref-type="table"} and [Fig 3](#pone.0178838.g003){ref-type="fig"}), but there was no statistical difference in blood flow (Pre-IR: 240.6±148.8 mL/min; Post-IR: 204.9 ± 111.1 mL/min, p = NS) and NMD (Pre-IR: 13.98 ± 6.04%; Post-IR: 11.30 ± 4.08%, p = NS).

3.3 Protocol 2 {#sec020}
--------------

### 3.3.1 Effect of celecoxib {#sec021}

Pre-IR baseline BA diameter, blood flow, and FMD were not different after celecoxib plus EA compared with EA alone. IR significantly blunted FMD responses in subjects who received celecoxib plus EA (Pre-IR: 11.05 ± 3.27%; Post-IR: 4.20 ± 1.68%, p = 0.001) ([Fig 4](#pone.0178838.g004){ref-type="fig"}). IR did not decrease blood flow in the celecoxib plus EA group (pre-IR 242.9 ± 57.6 mL/min, post-IR 209.2 ± 49.6 mL/min, P = NS). FMD was blunted to almost the same values observed in the sham EA group during protocol 1, demonstrating the potent inhibitory effect of celecoxib on EA-induced endothelial protection (EA only 9.47 ± 5.23% vs. celecoxib plus EA 4.20 ± 1.68%, P \< 0.05 compared with two-way ANOVA). Multivariate analysis adjusting age and gender determined that sham (HR (hazard ratio) 27.3, 95% CI (confidential interval) 4.6--162.5, P \< 0.001) and celecoxib (HR 14.6, 95% CI 1.3--160.3, P = 0.003) treatment were associated with endothelial dysfunction defined as FMD \< 6%.

![Box plots of the flow-mediated dilatation responses before and after ischemia-reperfusion following administration of celecoxib in the electroacupuncture group (protocol 2).](pone.0178838.g004){#pone.0178838.g004}

FMD was significantly blunted after IR, demonstrating that celecoxib prevented electroacupuncture-induced endothelial protection against IR. Boxes show interquartile ranges; the lower and upper boundaries of the boxes indicate the 25^th^ and 75^th^ percentile levels, respectively; and the horizontal lines within the boxes indicate the median levels. FMD: flow-mediated dilatation, IR: ischemia-reperfusion.

Discussion {#sec022}
==========

To the best of our knowledge, this study is the first to demonstrate the protective effects of EA against endothelial dysfunction and to verify the mechanistic significance of COX-2 in a human forearm IR model. We observed a significant blunting of FMD after IR in the sham control group, whereas EA prevented it. We observed a significant blunting of FMD after IR in the sham control group, whereas EA prevented it. Since EA treatment was performed on the contralateral side of IR injury, it also revealed that a big part of its mechanism relied on central pathways.

Previous animal studies have suggested that the mechanisms leading to such preconditioning---mimetic properties of EA is likely multifactorial, with modulation of the autonomic nervous system (ANS), endothelial nitric oxide synthase (eNOS), and inducible NOS all coming to play \[[@pone.0178838.ref015],[@pone.0178838.ref021],[@pone.0178838.ref022]\]. Especially in the treatment of cardiovascular diseases, modulation of the ANS by suppression of the sympathetic nervous system is acknowledged as one of the central therapeutic mechanisms of EA \[[@pone.0178838.ref016]\]. Studies have also shown that acupuncture needling on ST36, a point that was used in our trial as well, activates the synthesis of NO \[[@pone.0178838.ref015]\], which is the main modulator of local blood flow and vascular tone \[[@pone.0178838.ref023]\]. In IR injury animal models, acupuncture reduced infarct size via the general RISK pathway including anti-apoptotic effects through modulation of the PI3K/Akt pathway \[[@pone.0178838.ref024]\], and in the cortex, EA reduced infarct size by augmenting eNOS activity thereby increasing cerebral perfusion \[[@pone.0178838.ref025]\].

In non-acupuncture related clinical studies, the proposed endothelial protection mechanism has also emphasized the role of NO in the physiology of both ischemic and pharmacological preconditioning via a direct and cGMP-mediated opening of KATP channels \[[@pone.0178838.ref026],[@pone.0178838.ref027]\]. In endothelium-dependent vasodilation induced by IR injury, we had previously shown that administration of exenatide can prevent impairment and that this effect is mediated by KATP channel opening \[[@pone.0178838.ref005]\]. Andrew et al. also showed that rosuvastatin could prevent IR-induced conduit artery endothelial dysfunction and that this effect was regulated by a COX-2--dependent mechanism \[[@pone.0178838.ref004]\]. In 2010, a preliminary study in hypertensive patients suggested that 15 minutes of acupuncture could improve FMD and we saw similar effects using 20 minutes of EA in stroke patients \[[@pone.0178838.ref017], [@pone.0178838.ref018]\].

To further clarify the proposed mechanisms, specific inhibitors are utilized before inducing ischemia. Past studies have revealed that intravenous PG I2 given before ischemia reduced infarct size and administration of COX-2 inhibitors before infarction hindered the infarct size-limiting effects of late ischemic preconditioning \[[@pone.0178838.ref028]\]. Administration of iNOS inhibitor 24 hours after ischemic preconditioning inhibited the increased production of myocardial PGE2 and 6-keto-PGF1a, while administration of COX-2 inhibitors at the same period did not affect iNOS activity \[[@pone.0178838.ref029],[@pone.0178838.ref030]\].

Adding to the current field of knowledge, our study newly demonstrated that the endothelial protection afforded by EA disappears after administration of celecoxib, a COX-2 inhibitor, and suggests that COX-2 may be involved in the signaling pathway leading to EA-mediated protection in a human forearm IR model. In the area of pain research, where EA has been most actively explored, EA also induced its anti-nociceptive effects by modulation of COX-2 expression in the nervous system related to pain control. In a recent study, EA alleviated mechanical and thermal hypersensitivity after lumbar L5 spinal nerve ligation by inhibiting COX-2 expression in the spinal dorsal horn and this inhibition was as effective as the COX-2 inhibitor celecoxib \[[@pone.0178838.ref031]\]. Along these lines, we think that EA might induce activity similar to that of COX-2 by increasing the NO bioavailability in IR-induced endothelial dysfunction in a human conduit artery.

Limitations {#sec023}
-----------

Our study had a small sample size and was conducted at a single center. Endothelial dysfunction induced by IR injury was limited to the conduit circulation and our assessment did not include the coronary circulation or distal microcirculation, which are also of importance in clinical IR injury. The data were obtained from a sample of healthy volunteers who likely did not have impaired endothelium-dependent responses. Also, among the volunteers in protocol 2, EA non-responders may have been included. Future studies are necessary to investigate the potential clinical implications in greater detail.

Conclusions {#sec024}
-----------

This pilot trial is the first human evidence verifying the effects of EA on endothelial pharmacological preconditioning and suggests that it may be induced via a COX-2-dependent mechanism.

Ethics approval {#sec025}
---------------

Kyung Hee University Medical Centre Ethics Board.
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###### Acupuncture points.

PC5 & PC6, ST36 & ST37, and sham electroacupuncture points. PC: pericardium, ST: stomach.

(TIF)

###### 

Click here for additional data file.

###### Diagram of flow-mediated dilatation measurement.

Diagram showing how electroacupuncure was conducted and how flow-mediated dilatation was measured on subjects. FMD: flow-mediated dilatation, IR: ischemia-reperfusion.

(TIF)
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Click here for additional data file.

###### CONSORT checklist.

Consolidated Standards of Reporting Trials checklist.

(DOC)
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Click here for additional data file.

###### Original trial protocol.

Original Korean version of trial protocol.

(DOC)
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Click here for additional data file.

###### Translated trial protocol.

Translated version of original trial protocol.

(DOCX)
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Click here for additional data file.

###### Individual data points.

Individual data points of the study.

(XLSX)
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Click here for additional data file.
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